NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
![](https://static.wixstatic.com/media/cd6738_17cceaf442cb4867b31c9dac92d367e1~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_17cceaf442cb4867b31c9dac92d367e1~mv2.webp)
![NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT](https://static.wixstatic.com/media/cd6738_17cceaf442cb4867b31c9dac92d367e1~mv2.jpeg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_17cceaf442cb4867b31c9dac92d367e1~mv2.webp)
![](https://static.wixstatic.com/media/cd6738_6ada5eee354849f48f7918e774ba510e~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_6ada5eee354849f48f7918e774ba510e~mv2.webp)
![NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6](https://static.wixstatic.com/media/cd6738_6ada5eee354849f48f7918e774ba510e~mv2.jpg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_6ada5eee354849f48f7918e774ba510e~mv2.webp)
- Dec 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
![](https://static.wixstatic.com/media/cd6738_d6eb75b9ef39407a810e9b830de3d868~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_d6eb75b9ef39407a810e9b830de3d868~mv2.webp)
![NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM](https://static.wixstatic.com/media/cd6738_d6eb75b9ef39407a810e9b830de3d868~mv2.jpeg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_d6eb75b9ef39407a810e9b830de3d868~mv2.webp)
- Dec 1, 2022
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM
![](https://static.wixstatic.com/media/cd6738_418ad50c67df496483e8ec2c253b3b2e~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_418ad50c67df496483e8ec2c253b3b2e~mv2.webp)
![NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)](https://static.wixstatic.com/media/cd6738_418ad50c67df496483e8ec2c253b3b2e~mv2.jpeg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_418ad50c67df496483e8ec2c253b3b2e~mv2.webp)
- Dec 1, 2022
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
![](https://static.wixstatic.com/media/cd6738_a3130931fe404c70b13bb3308a7ef4c8~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_a3130931fe404c70b13bb3308a7ef4c8~mv2.webp)
![NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM](https://static.wixstatic.com/media/cd6738_a3130931fe404c70b13bb3308a7ef4c8~mv2.jpeg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_a3130931fe404c70b13bb3308a7ef4c8~mv2.webp)
- Dec 1, 2022
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
![](https://static.wixstatic.com/media/cd6738_e435f4977ad347689b8e3eaa267e828a~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_e435f4977ad347689b8e3eaa267e828a~mv2.webp)
![NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma](https://static.wixstatic.com/media/cd6738_e435f4977ad347689b8e3eaa267e828a~mv2.jpeg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_e435f4977ad347689b8e3eaa267e828a~mv2.webp)
- Dec 1, 2022
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
![](https://static.wixstatic.com/media/cd6738_b1796c7560384018bccfbdf287731bda~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_b1796c7560384018bccfbdf287731bda~mv2.webp)
![NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex](https://static.wixstatic.com/media/cd6738_b1796c7560384018bccfbdf287731bda~mv2.jpg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_b1796c7560384018bccfbdf287731bda~mv2.webp)
- Dec 1, 2022
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
![](https://static.wixstatic.com/media/cd6738_9a4a94d4db64476c861068b7225c5f9d~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_9a4a94d4db64476c861068b7225c5f9d~mv2.webp)
![NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7](https://static.wixstatic.com/media/cd6738_9a4a94d4db64476c861068b7225c5f9d~mv2.jpg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_9a4a94d4db64476c861068b7225c5f9d~mv2.webp)
- Dec 1, 2022
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
![](https://static.wixstatic.com/media/cd6738_f976fcd13fe849c8a0a750454a87ba64~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_f976fcd13fe849c8a0a750454a87ba64~mv2.webp)
![NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)](https://static.wixstatic.com/media/cd6738_f976fcd13fe849c8a0a750454a87ba64~mv2.jpg/v1/fill/w_320,h_240,fp_0.50_0.50,q_90,enc_auto/cd6738_f976fcd13fe849c8a0a750454a87ba64~mv2.webp)
- Dec 1, 2022
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)